| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Lance Berberian | Evp, Special Advisor, Strategy | 18,652 | 0 | 31 Mar, 2025 |
| Jean-Luc Belingard | - | 17,781 | 0 | 08 Feb, 2024 |
| Anita Z Graham | Evp, Chro | 5,185 | 0 | 30 Mar, 2026 |
| Glenn A Eisenberg | Executive Vice President | 37,920 | 0 | 31 Mar, 2025 |
| Kerrii B Anderson | - | 9,563 | 0 | 13 Feb, 2026 |
| R Sanders Williams | - | 8,120 | 0 | 08 Feb, 2024 |
| Adam H Schechter | President Ceo | 113,137 | 0 | 30 Mar, 2026 |
| Peter J Wilkinson | Svp, Chief Accounting Officer | 1,852 | 0 | 30 Mar, 2026 |
| Garheng Kong | - | 13,739 | 0 | 13 Feb, 2026 |
| Jonathan P. Divincenzo | Evp, Pres, Central Labs Intl | 5,461 | 0 | 29 Mar, 2024 |
| Der Vaart Sandra D Van | Evp, Corporate Affairs | 6,239 | 0 | 30 Mar, 2026 |
| Paul Rothman | - | 2,571 | 0 | 13 Feb, 2026 |
| Dwight Gary Gilliland | - | 6,656 | 0 | 01 Aug, 2025 |
| Jeffrey A. Davis | - | 5,460 | 0 | 13 Feb, 2026 |
| Brian J Caveney | Evp, Pres Of Ed, Cmo Cso | 36,492 | 0 | 30 Mar, 2026 |
| Kathryn E Wengel | - | 4,133 | 0 | 13 Feb, 2026 |
| Judith C Seltz | Evp, Chro | 4,182 | 0 | 03 Apr, 2023 |
| Paul R Kirchgraber | Ceo, Covance Drug Development | 12,946 | 0 | 23 May, 2023 |
| Mark S Schroeder | Evp, Pres Diagnostics Coo | 12,677 | 0 | 30 Mar, 2026 |
| Amy B. Summy | Evp, Chief Marketing Officer | 7,880 | 0 | 30 Mar, 2026 |
| Julia Aijun Wang | Chief Financial Officer, Evp | 1,817 | 0 | 13 Feb, 2026 |
| Kirsten Marie Kliphouse | - | 3,160 | 0 | 13 Feb, 2026 |
| Megan D. Bailey | Evp, Pres, Central Labs Intl | 4,851 | 0 | 30 Mar, 2026 |
| Akinbolade Oyegunwa | Evp, Cio Cto | 5,064 | 0 | 30 Mar, 2026 |
| Kathryn W Kyle | Evp, Chief Legal Officer | 4,575 | 0 | 30 Mar, 2026 |
| Jonathan C Meltzer | Evp, Operations | 3,620 | 0 | 30 Mar, 2026 |
| Bryan T Vaughn | Evp, Diagnostics | 6,746 | 0 | 30 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Mar, 2026 | Megan D. Bailey | Common Stock | A | 1,184 | $0.00 | 5,332 | D | A |
| 26 Mar, 2026 | Adam H Schechter | Common Stock | A | 58,470 | $0.00 | 139,243 | D | A |
| 26 Mar, 2026 | Bryan T Vaughn | Common Stock | A | 1,584 | $0.00 | 7,197 | D | A |
| 26 Mar, 2026 | Peter J Wilkinson | Common Stock | A | 2,388 | $0.00 | 4,240 | D | A |
| 26 Mar, 2026 | Mark S Schroeder | Common Stock | A | 9,304 | $0.00 | 15,777 | D | A |
| 26 Mar, 2026 | Jonathan C Meltzer | Common Stock | A | 2,388 | $0.00 | 5,170 | D | A |
| 26 Mar, 2026 | Kathryn W Kyle | Common Stock | A | 1,584 | $0.00 | 5,026 | D | A |
| 26 Mar, 2026 | Akinbolade Oyegunwa | Common Stock | A | 1,340 | $0.00 | 5,446 | D | A |
| 26 Mar, 2026 | Der Vaart Sandra D Van | Common Stock | A | 6,382 | $0.00 | 8,961 | D | A |
| 26 Mar, 2026 | Amy B. Summy | Common Stock | A | 3,994 | $0.00 | 9,716 | D | A |
| 26 Mar, 2026 | Peter J Wilkinson | Common Stock | A | 2,388 | $0.00 | 4,240 | D | A |
| 26 Mar, 2026 | Der Vaart Sandra D Van | Common Stock | A | 6,382 | $0.00 | 8,961 | D | A |
| 26 Mar, 2026 | Adam H Schechter | Common Stock | A | 58,470 | $0.00 | 139,243 | D | A |
| 26 Mar, 2026 | Amy B. Summy | Common Stock | A | 3,994 | $0.00 | 9,716 | D | A |
| 26 Mar, 2026 | Jonathan C Meltzer | Common Stock | A | 2,388 | $0.00 | 5,170 | D | A |
| 26 Mar, 2026 | Mark S Schroeder | Common Stock | A | 9,304 | $0.00 | 15,777 | D | A |
| 26 Mar, 2026 | Bryan T Vaughn | Common Stock | A | 1,584 | $0.00 | 7,197 | D | A |
| 26 Mar, 2026 | Anita Z Graham | Common Stock | A | 6,604 | $0.00 | 8,064 | D | A |
| 26 Mar, 2026 | Akinbolade Oyegunwa | Common Stock | A | 1,340 | $0.00 | 5,446 | D | A |
| 26 Mar, 2026 | Brian J Caveney | Common Stock | A | 9,304 | $0.00 | 39,411 | D | A |